Bli medlem
Bli medlem

Du är här


Immunovia AB: Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Immunovia and NCI (National Cancer Institute), has in a memorandum of
understanding agreed to collaborate towards a common goal of cancer
biomarker development and validation, in particular regarding early
detection of pancreatic cancer in the risk group of new onset
diabetes over 50 years.

LUND, Sweden - Immunovia AB is delighted to announce a collaboration
with the Early Detection Research Network (EDRN) which is a program
within the National Cancer Institute (NCI) with a mission to
discover, develop, and validate biomarkers for risk assessment,
detection, and molecular diagnosis and prognosis of early cancer. The
overall goal of EDRN is to establish validated cancer biomarkers that
are ready for large-scale clinical testing to improve early cancer

Under a Memorandum of Understanding signed for the collaboration, the
NCI EDRN and Immunovia intend to:

- establish a framework for cooperation between Immunovia and NCI for validation projects designed to improve early cancer diagnosis, particularly regarding early detection of pancreatic cancer in the newly onset diabetes risk group.
- exchange scientific information on relevant biomarkers to be
considered for validation

- identify other joint opportunities relevant to the missions of the
NCI EDRN and Immunovia

Pancreatic cancer has one of lowest survival rates of any major cancer
type and a mortality exceeding breast cancer. The key to improve
prognosis lies in early detection. Based on a number of clinical
trials, Immunovia has identified the first blood based biomarker test
that now will be validated in hereditary high risk individuals
undergoing annual screening for early pancreatic cancer detection.

"It is Immunovia's intention to expand the validation studies of
IMMrayTM PanCan -d to the risk group of newly onset diabetic
patients. This collaboration with EDRN of the National Cancer
Institute in USA is a very important step to achieve this. Patients
aged over 50 suffering from diabetes are a large group and their risk
for developing pancreatic cancer is up to 6-8 times greater than
normal", clearly an important clinical unmet need, commented Mats
Grahn, CEO, Immunovia.

"The NCI EDRN and Immunovia share a common desire to further
cooperation and partnership in the field of cancer biomarker
development and validation, and we acknowledge the importance of
public/private partnerships to advancing cancer research. Early
detection of pancreatic cancer in high risk groups such as newly
onset diabetes is a key to improved survival in this devastating
disease. We are pleased to work together with Immunovia to reach
these goals", commented Sudhir Srivastava, Ph.D, Chief, Cancer
Biomarkers Research Group, Division of Cancer Prevention, NCI.

For more information, please contact:

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230


About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department
of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's
strategy is to decipher the wealth of information in blood and
translate it into clinically useful tools to diagnose complex
diseases such as cancer, earlier and more accurately than previously
possible. Immunovia's core technology platform, IMMray™, is based on
antibody biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early diagnosis
of pancreatic cancer. In the beginning of 2016, the company started a
program focused on autoimmune diseases diagnosis, prognosis and
therapy monitoring. The first test from this program, IMMray™ SLE-d,
is a biomarker signature derived for differential diagnosis of lupus,
now undergoing evaluation and validation. (Source:

This information is information that Immunovia AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above.

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in
Stockholm and Wildeco is the company's Certified Adviser. For more
information, please visit


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.